INTRODUCTIONLiver is an organ, which, most often, metastasizes from the colorectal carcinoma, breast carcinoma, malignant lung tumor, and malignant genitourinary tract tumor. Surgery of liver metastases is indicated if the disease is limited to liver, when the primary tumor was radically removed. In some specific cases, a synchronized resection of the primary tumor (most often colon tumor) and resection of the metastatic disease are performed. This is the reason why the diagnostics of the extrahepatic disease, after any surgically treated malignity, is of primary importance before consideration of any surgery of metastases (1-3). Metastases appearing only in liver are rare and mostly originate from the colorectal carcinoma. The only therapy, which may lead to healing, is surgical removal of metastases. In everyday surgical practice, the number of patients, operated on due to liver metastases of the colorectal carcinoma is very small in comparison to frequency of the primary carcinoma and its tendency to metastasize (4,5). Unfortunately, at this moment, surgical resection of colorectal carcinoma metastases is possible in only 15% to 25% of cases (6,7). Operative treatment of liver metastases is justified only if there is a probability that healing is achievable. In practice, unfortunately, it is difficult to define the term probability of healing because the published papers sometimes lack details. Excision of one or more metastases from liver can be performed only if all the observed metastatic changes can be removed and if there is no such metastatic change left, which is not visible during the operation, but which is confirmed by visual techniques. In practice, this means that not only those metastases, easily visible should be removed.Those barely visible or invisible should not be left over. Basic indications for liver resection due to liver metastases are that they are not present in other organs, such as lungs or brain. Besides this, it is performed in all other cases, regardless the number of metastases, if after resection, there is, at least 25% of total volume of healthy liver tissue left, i.e. about 40% of total liver volume if the aggressive neoadjuvant therapy was applied (8, 9). Local recurrences of rectal tumor in pelvis minor and carcinosis of diaphragm are not contraindications for liver resection if a protective clearance up to a healthy tissue can be achieved. These principles, when they are respected, give good results and five-year survival is from 30% to 40% (7-13). About 25% of patients with colorectal carcinoma show presence of portogenic metastases in liver during the initial operation. Metachronous metastases are discovered later, after the initial operation, and they occur in 30% of patients. Synchronous metastases of colorectal carcinoma may be removed during the initial surgery or after some time by a new surgery (13). Chemotherapy and biological therapy may increase an overall resectability rate, which enables the surgeons to perform resection in additional 15% to 30% of patients wit...
In some patients and when performed by a skillful surgeon, gynecologic oncologist familiar with advanced laparoscopic techniques, laparoscopy results with less surgical trauma, reduced blood loss and hospitalization, and faster recovery. The complication rate has been found to increase as the complexity of the operation rises, but it is not higher than in open surgery. Preliminary studies show that recurrence and survival rates are comparable to those reported for patients treated by a standard abdominal approach. Future randomised trials are necessary to deal with long term recurrences and survival data and benefits of laparoscopy in management of gynecologic malignancies. At our institution 97 cancer patients underwent laparoscopic procedures, without complications: explorative and staging laparoscopies with biopsies of ovaries, peritoneal biopsies, retroperitoneal and mesenteric tumours; second look laparoscopy, ovariectomy, laparoscopic assisted vaginal hysterectomy (LAVH). Advanced ovarian cancer was found in 3 patients and laparotomy was performed. No complications were established.
Idiopathic granulomatous mastitis is an uncommon benign breast disease diagnosed from exclusion. It mimics malignant breast tumor in terms of clinical and imaging features. We hereby report a case of painful lump in the left breast. Mammograms and ultrasound findings could not exclude malignant mass. Wide excision was performed and the final histopathological diagnosis of granulomatous mastitis was concluded. In conclusion, the clinical and imaging findings of granulomatous mastitis are similar to carcinoma. Tissue diagnosis was very important to distinguish these two entities before starting management and avoiding unnecessary mastectomy.
Background: Hepatectomies are mostly performed for the treatment of hepatic benign or malignant neoplasms, intrahepatic gallstones, or parasitic cysts of the liver. The most common malignant neoplasms of the liver are metastases from colorectal cancer. Anatomic liver resection involves two or more hepatic segments, while non-anatomic liver resection involves resection of the metastases with a margin of uninvolved tissue. The aim of this manuscript was to show results of hepatectomies performed at the Oncology Institute of Vojvodina. Methods: We performed 133 liver resections from January 1997 to December 2013. Clinical and histopathological data were obtained from operative protocols, histopathological reports, and patients? medical histories. Results: We did 80 metastasectomies, 51 segmentectomies, and 18 radiofrequent ablations (RFA). Average number of colorectal cancer metastases was 1.67 per patient. We also made 10 left hepatectomies. In all cases, we made non-anatomic resections. Conclusion: Decision about anatomic versus non-anatomic resections for colorectal metastasis and primary liver tumors should be made before surgical exploration. Preservation of liver parenchyma is important with respect to liver failure and postoperative chemotherapy treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.